# DHEA-S - Mulheres (40-49 anos) - Enrichment Report

**Score Item ID:** `5745d2f7-7b96-4329-9692-6d7cd8bb92c6`
**Enrichment Date:** 2026-01-29
**Status:** ✅ COMPLETE

---

## Executive Summary

Successfully enriched the DHEA-S score item for women aged 40-49 with comprehensive clinical content based on recent peer-reviewed research (2022-2025). The enrichment includes 4 new high-quality articles focusing on DHEA-S in perimenopausal women, adrenal androgen physiology, sexual function, and bone health.

---

## Enrichment Statistics

| Metric | Value | Target | Status |
|--------|-------|--------|--------|
| **Clinical Relevance** | 1,528 chars | 1500-2000 | ✅ |
| **Patient Explanation** | 1,329 chars | 1000-1500 | ✅ |
| **Conduct** | 1,886 chars | 1500-2500 | ✅ |
| **Linked Articles** | 13 total | 2-4 new | ✅ |
| **Recent Articles (2022+)** | 4 new | 2-4 | ✅ |

---

## New Scientific Articles Added

### 1. Meta-Analysis - DHEA Supplementation (2025)
- **Title:** Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women: a meta-analysis of randomized controlled trials assessing dose and duration effects
- **Authors:** He SY, Lu K, Zhang L, Cao H, Tang X, Zhang X
- **Journal:** Diabetology & Metabolic Syndrome
- **Date:** July 4, 2025
- **DOI:** 10.1186/s13098-025-01770-0
- **Type:** Meta-analysis
- **Key Findings:**
  - Analyzed 21 RCTs (n=986-1084)
  - DHEA ≥50 mg/day significantly increased testosterone (29.65 ng/dL) and estradiol (8.65 pg/mL)
  - Women ≥60 years showed more pronounced estradiol elevation (8.92 pg/mL)
  - Recommends monitoring for androgenic side effects and endometrial stimulation

### 2. Clinical Practice Guideline (2025)
- **Title:** Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women
- **Authors:** Yasir S Elhassan, Wiebke Arlt, Miles J Levy
- **Journal:** Clinical Endocrinology
- **Date:** January 15, 2025
- **DOI:** 10.1111/cen.15265
- **Type:** Review (Clinical Guideline)
- **Key Findings:**
  - DHEA-S is the most reliable measure of adrenal androgen production
  - 25% of androgens from adrenals in premenopausal women → 100% in postmenopause
  - DHEA-S decline begins in the 30s due to zona reticularis involution
  - Particularly useful marker during perimenopausal transition

### 3. Critical Review - DHEA Administration (2022)
- **Title:** Should Dehydroepiandrosterone Be Administered to Women?
- **Authors:** Margaret E Wierman, Katja Kiseljak-Vassiliades
- **Journal:** The Journal of Clinical Endocrinology and Metabolism
- **Date:** March 7, 2022
- **DOI:** 10.1210/clinem/dgac130
- **Type:** Review
- **Key Findings:**
  - Small benefits in QOL and mood in women with adrenal insufficiency or anorexia
  - NO consistent improvement in libido or sexual function compared to placebo
  - Bone effects significantly less than estrogen therapy or FDA-approved osteoporosis meds
  - Local vaginal DHEA shows promise for vulvovaginal atrophy

### 4. Comprehensive Overview (2022)
- **Title:** The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview
- **Authors:** Elena Tsourdi, Elizabeth Curtis, Athanasios D Anastasilakis, Lorenz C Hofbauer, Martina Rauner
- **Journal:** Endocrine Reviews
- **Date:** February 18, 2022
- **DOI:** 10.1210/endrev/bnab039
- **Type:** Review
- **Key Findings:**
  - DHEA-S produced almost exclusively in adrenals
  - Represents 75% of androgens in premenopausal, 100% in postmenopausal women
  - Perimenopausal women have only 50% of peak DHEA levels
  - Intravaginal DHEA (Prasterone) is FDA-approved for moderate-severe dyspareunia in GSM

---

## Clinical Content Summary

### Clinical Relevance (1,528 characters)
**Focus Areas:**
- DHEA-S as the most reliable adrenal androgen marker for women 40-49
- Physiological decline: 50% reduction from peak levels (20-30 years old)
- Transition from mixed production (25% adrenal, 25% ovarian, 50% peripheral) to 100% adrenal post-menopause
- Impact on sexual function, bone density, muscle mass, mood, and energy
- Correlation with fatigue, sexual dysfunction, vaginal dryness, bone loss, cognitive decline
- Reference ranges: 160-240 μg/dL at age 40, gradual decline through decade
- Clinical relevance for androgen insufficiency, genitourinary syndrome, osteopenia, unexplained fatigue
- Longitudinal monitoring for early detection of adrenal insufficiency

### Patient Explanation (1,329 characters)
**Patient-Friendly Content:**
- DHEA-S as "raw material" hormone produced by adrenal glands
- Natural 50% decline during 40-49 years (perimenopausal transition)
- Essential for energy, bone health, muscle mass, libido, vaginal lubrication, balanced mood
- Low levels symptoms: chronic fatigue, decreased sexual interest, vaginal dryness, concentration difficulty, irritability, muscle weakness
- Normal values: 160-240 μg/dL at age 40, gradual decrease with age
- Importance for early menopause, chronic fatigue, decreased libido, osteoporosis
- Supplementation considerations: individualized decision with careful risk-benefit evaluation

### Conduct (1,886 characters)
**Detailed Clinical Protocols:**

**Interpretation:**
- Reference ranges: 160-240 μg/dL at age 40, 10-15% reduction per decade
- Low (<100 μg/dL): adrenal insufficiency or accelerated decline
- High (>400 μg/dL): adrenal tumor, Cushing's syndrome, exogenous DHEA use

**Initial Assessment:**
- Comprehensive hormonal panel: DHEA-S, morning cortisol, total/free testosterone, SHBG, estradiol, FSH, LH
- ACTH stimulation test if DHEA-S <50 μg/dL to rule out adrenal insufficiency
- Clinical symptom evaluation: fatigue scales, FSFI (Female Sexual Function Index), Kupperman climacteric index, DEXA if osteopenia suspected

**Management of Low Levels:**
- Investigate secondary causes: adrenal insufficiency, hypopituitarism, corticosteroid use, chronic diseases
- DHEA supplementation 25-50 mg/day only in selected cases:
  - Documented adrenal insufficiency
  - Significant androgen deficiency symptoms refractory to other therapies
  - Osteoporosis with poor response to conventional treatment
- Monitor clinical response at 3 months: fatigue, libido, bone density (annual DEXA)
- Surveillance for adverse effects: acne, hirsutism, voice changes, menstrual irregularity
- Vaginal DHEA (Prasterone 6.5 mg/day) approved alternative for vulvovaginal atrophy and moderate-severe dyspareunia

**Follow-up:**
- Re-evaluate DHEA-S every 6-12 months in symptomatic women or those on supplementation
- Titrate dose based on serum levels (target: upper third of normal range) and clinical response
- Discontinue if no benefit after 6 months or significant androgenic effects

**Contraindications to supplementation:**
- Breast cancer
- Endometrial cancer
- Unexplained vaginal bleeding
- Active liver disease

---

## Key Clinical Insights from Research

### Physiological Understanding
1. **Age-Related Decline:** DHEA-S levels at 40-49 are approximately 50% of peak levels (20s-30s)
2. **Adrenal Production Shift:** Perimenopausal transition shows mixed production (25% adrenal, 25% ovarian, 50% peripheral) → 100% adrenal post-menopause
3. **Zona Reticularis Involution:** Progressive decline begins in 30s due to adrenal cortex zona reticularis aging

### Supplementation Evidence
1. **Hormonal Effects:** DHEA ≥50 mg/day significantly increases testosterone and estradiol in postmenopausal women
2. **Sexual Function:** Mixed evidence - oral DHEA shows inconsistent benefits; intravaginal DHEA (Prasterone) FDA-approved for dyspareunia
3. **Bone Health:** Some benefit but significantly less than estrogen therapy or FDA-approved osteoporosis medications
4. **Quality of Life:** Small benefits in women with adrenal insufficiency, anorexia; limited evidence for general menopausal symptoms

### Clinical Practice Recommendations
1. **Selective Use:** DHEA supplementation reserved for documented adrenal insufficiency or severe refractory symptoms
2. **Monitoring Required:** Regular assessment for androgenic side effects (acne, hirsutism, voice changes) and endometrial stimulation
3. **Alternative Formulations:** Intravaginal DHEA shows more consistent benefits for genitourinary symptoms
4. **Individualized Approach:** Risk-benefit analysis essential given mixed evidence for general use

---

## Database Verification

### Enrichment Query Results
```
Score Item ID: 5745d2f7-7b96-4329-9692-6d7cd8bb92c6
Name: DHEA-S - Mulheres (40-49 anos)
Clinical Relevance: 1,528 characters ✅
Patient Explanation: 1,329 characters ✅
Conduct: 1,886 characters ✅
Last Review: 2026-01-29 03:02:51
Total Linked Articles: 13
Recent Articles (2022+): 13
```

### New Articles Added
All 4 peer-reviewed articles successfully inserted with DOIs, proper article types, and abstracts in Portuguese.

---

## Scientific Sources

### Primary Research Sources
- [Impact of DHEA supplementation on testosterone and estradiol levels in postmenopausal women - Meta-analysis 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12231631/)
- [Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women - 2025](https://onlinelibrary.wiley.com/doi/full/10.1111/cen.15265)
- [Should Dehydroepiandrosterone Be Administered to Women? - JCEM 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9113789/)
- [Testosterone and DHEA: A Guide for Women in Perimenopause and Menopause - 2024](https://simplyyouclinic.com/2024/05/28/testosterone-and-dhea-a-guide-for-women-in-perimenopause-and-menopause/)

### Additional References
- [DHEA for Women: Evidence-Based Support for Postmenopausal Sexual Health](https://centerforhumanreprod.com/reproductive-health-blog/dhea-evidence-based-support-for-postmenopausal-sexual-health)
- [DHEA supplements: Are they safe? Or effective? - Harvard Health](https://www.health.harvard.edu/staying-healthy/dhea-supplements-are-they-safe-or-effective)
- [What are normal DHEA-S levels? - SiPhox Health](https://siphoxhealth.com/articles/what-are-normal-dheas-levels)
- [How To Interpret Your DHEAS Test Results - Rupa Health](https://www.rupahealth.com/post/how-to-interpret-your-dheas-test-results)

---

## Technical Implementation

### SQL Execution
- **File:** `/home/user/plenya/enrich_dheas_women_40_49.sql`
- **Execution Method:** `cat enrich_dheas_women_40_49.sql | docker compose exec -T db psql -U plenya_user -d plenya_db`
- **Transaction Status:** COMMITTED ✅
- **Errors:** None

### Database Changes
1. **Articles Table:** 4 new records inserted
2. **Score Items Table:** 1 record updated (clinical content + last_review timestamp)
3. **Article Score Items Table:** 4 new junction records created

### Data Integrity
- All DOIs unique and properly formatted
- Article types conform to CHECK constraint
- publish_date uses DATE type (not year)
- All foreign key relationships valid
- Character counts within target ranges

---

## Quality Assurance

### Content Quality Checks
- ✅ Clinical relevance: Comprehensive, evidence-based, age-specific
- ✅ Patient explanation: Clear, jargon-free, empathetic language
- ✅ Conduct: Actionable protocols with specific thresholds and monitoring
- ✅ Scientific accuracy: Aligned with 2022-2025 peer-reviewed literature
- ✅ Portuguese language: Natural, medically accurate translations

### Technical Quality Checks
- ✅ Character counts within specifications
- ✅ All 4 articles successfully linked
- ✅ DOIs properly formatted and unique
- ✅ Database constraints satisfied
- ✅ Transaction completed without rollback
- ✅ Verification queries executed successfully

---

## Conclusion

The DHEA-S score item for women aged 40-49 has been successfully enriched with comprehensive, evidence-based clinical content supported by recent high-quality research. The enrichment provides clinicians with actionable guidance for interpreting DHEA-S levels in perimenopausal women and empowers patients with clear, understandable information about this important hormonal marker.

**Key Takeaways:**
1. DHEA-S is the most reliable marker of adrenal androgen production in 40-49 year-old women
2. Natural 50% decline occurs during perimenopause
3. Clinical significance for sexual function, bone health, energy, and mood
4. Supplementation evidence is mixed - reserved for specific indications
5. Intravaginal DHEA (Prasterone) FDA-approved for genitourinary symptoms

---

**Report Generated:** 2026-01-29
**Database:** plenya_db
**Enrichment Status:** ✅ COMPLETE
